PM54 clinical trials
PM54 is named as an intervention in 3 current clinical trials in our USA, Spain, Germany, France, Portugal and Belgium registers. 2 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is PharmaMar. The most-studied condition is Advanced Solid Tumor. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for PM54
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of PM54
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
NCT07644039 · Advanced Malignancies
|
Phase 1/2 | Recruiting | PharmaMar | USA, Spain |
|
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
NCT05841563 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1 | Recruiting | PharmaMar | USA, Spain, Belgium |
|
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT07839819 · Advanced Solid Tumor
|
Phase 1/2 | Not yet open | PharmaMar | USA, Germany, France, Portugal |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
PM54 in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing PM54. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies
2025-523774-16-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Ongoing | Pharma Mar S.A | Spain, France, Italy |
Conditions studied with PM54
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| PharmaMar | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in Germany | 1 | 0 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Portugal | 1 | 0 |
| Clinical trials in Belgium | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about PM54 trials
How many clinical trials are testing PM54?
3 current trials in our USA, Spain, Germany, France, Portugal and Belgium registers name PM54 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are PM54 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in Spain and 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors PM54 clinical trials?
The lead sponsor is PharmaMar. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how PM54 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PM54 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PM54 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.